



2nd October 2025

Vitasora Locks In High-Growth Home Care Partnership with Iris Medical Group Covering 12,000+ Patients

Highlights

- New partnership with **Iris Medical Group (IMG)**, a leading in-home care provider operating in Tennessee, Kentucky, and Indiana, and expanding across the southeast United States.
- IMG currently manages **12,000+ patients** performing primary care, transition care, palliative care, wound care, and psychiatric care, and takes on in excess of **3,000 new transition patients per month** through partnerships with major healthcare Organizations and their facilities.
- Vitasora's Connected Care services are now to be embedded across IMG's home-based health care services.
- **65+ clinicians** to directly consent/enrol patients, anticipated to drive **50%+ increase in enrolment and availability of care** for patients.
- First patients to be enrolled from **Mid-November 2025**, with patient care starting immediately and associated revenue flowing **30–60 days later**.

Vitasora Health Limited (ASX:VHL; OTCQB:VHLUF) ("Vitasora" or "the Company"), a leader in the delivery of AI-powered, Connected Care solutions in the U.S. healthcare market, is pleased to announce a new value-based care contract with Iris Medical Group (IMG), a large and rapidly growing in-home care providers in the southern United States.

IMG is a leader in the delivery of high-quality, home-based primary, transitional and other aspects of care to **12,000+ patients** in the southeast United States, including the ongoing addition of over **3,000 new patient transitions per month** through large-scale partnerships with hospitals and healthcare groups that reduce readmission rates and improve the continuity and quality in Tennessee, Kentucky, Indiana, and expanding across the southeast United States.

This announced partnership will integrate Vitasora's Connected Care Management services, including Remote Patient Monitoring (RPM) and Chronic Care Management (CCM), into IMG's model of care to support patients between visits and reduce unnecessary hospitalisations. Crucially, IMG's growing group of practitioners (65+ currently) will enrol patients directly into Vitasora's care programs, with an anticipated 50%+ enrolment rate, well above industry averages.

Program implementation is well underway, with first patient enrolments scheduled to commence in mid-November 2025. Without delay, Vitasora and IMG expect to enrol between 500 and 1,000 new

ASX ANNOUNCEMENT

ASX:VHL OTCQB:VHLUF



patients by year-end, reflecting strong clinical engagement and operational alignment between both organisations and with this number forecast to continue to grow rapidly in 2026. Vitasora anticipates generating between US\$50-US\$90 per patient per month fee-for-service revenues which is aligned with stated Company objectives.

The contract has a 12 month term that is automatically renewed at the end of the term. Either party may terminate the contract with no fault giving 60 days notice which is not a typical contract clause in the US healthcare arena.

Iris Medical Group is a physician-owned provider of in-home primary, transitional, and chronic care services, operating across Tennessee, Mississippi, Texas, Indiana, and Alabama.

Marjan Mikel, CEO of Vitasora, said: *"This partnership is a great example of innovation in action. Iris Medical Group delivers trusted care inside the home, and Vitasora brings the digital layer to extend that care 24/7. Together, we're creating a proactive, scalable model that keeps people healthier at home and out of hospital."*

Dr Joel Parker, CEO of Iris Medical Group, added: *"Our mission has always been to meet patients where they are—and now, with Vitasora, we can continue supporting them between these home visits. This partnership will help us drive better outcomes while delivering care with compassion and precision."*

This partnership with Iris Medical Group is another example of how the Vitasora model continues to gain strong traction with leading healthcare organisations across the U.S. The Company remains focused on executing at scale, with internal systems and onboarding processes being continually optimised to meet growing demand. Vitasora's clinical operations team is also expanding to ensure seamless delivery and quality outcomes across all contracted programs.

With momentum accelerating and multiple commercial discussions in advanced stages, the Company anticipates announcing further high-impact partnerships in the near term. Vitasora will continue to keep investors closely informed of patient enrolment progress, contract execution milestones, and the scale-up of clinical operations as it delivers on its growth strategy.

For further information, investors and media please contact:

Mr Marjan Mikel

CEO & Managing Director

Vitasora Health Limited

P: +61 408 462 873

Mr Nicholas Smedley

Non-Executive Chairman

Vitasora Health Limited

P: +61 447 074 160

ASX ANNOUNCEMENT

ASX:VHL OTCQB:VHLUF



E: marjan@vitasorahealth.com

E: nicholas@vitasorahealth.com

This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:RSHUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.vitasorahealth.com.au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respi™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respi.co/us/> or for [wheezo®](#)

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora's current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of

ASX ANNOUNCEMENT

ASX:VHL OTCQB:VHLUF



Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.